Column Group LLC holds a concentrated book of 3 stocks worth $100.7M as of Q1 2026 (disclosed May 18, 2026, a ~45-day 13F lag). Their largest long position is Surrozen, Inc. at 55% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1833486/holdings"
Use Arkolith to show Column Group LLC's latest holdings, largest changes, and filing provenance.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
0% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Column Group LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| VANGUARD GROUP INC | 3 / 3 | $1.4B |
| BlackRock, Inc. | 3 / 3 | $1.2B |
| VANGUARD CAPITAL MANAGEMENT LLC | 3 / 3 | $865.8M |
| FMR LLC | 3 / 3 | $854.0M |
| STATE STREET CORP | 3 / 3 | $475.6M |
| UBS Group AG | 3 / 3 | $429.5M |
| GEODE CAPITAL MANAGEMENT, LLC | 3 / 3 | $348.3M |
| GOLDMAN SACHS GROUP INC | 3 / 3 | $231.3M |
Ranked by how many of Column Group LLC's top 3 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Surrozen, Inc. COM | $55.8M | 1.92M | 55.4% | ▲+3.5% Added · +66K sh | |
| 2 | ORIC Pharmaceuticals Inc. COM | $44.9M | 3.54M | 44.5% | —Held | |
| 3 | Revolution Medicines Inc COM | $4K | 46 | 0.0% | —Held |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 18, 2026 | 3 | $100.7M | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 13, 2026 | 5 | $82.8M | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 5 | $81.0M | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 15, 2025 | 5 | $65.7M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 14, 2025 | 5 | $44.2M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 5 | $55.7M | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 6 | $69.6M | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 15, 2024 | 6 | $71.3M | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 7 | $160.5M | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 9, 2024 | 6 | $151.4M | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 13, 2023 | 7 | $150.6M | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Jul 24, 2023 | 7 | $257.7M | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 7 | $276.6M | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 13, 2023 | 7 | $300.4M | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 7 | $451.8M | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 12, 2022 | 7 | $469.9M | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 16, 2022 | 7 | $539.4M | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 11, 2022 | 7 | $735.3M | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 12, 2021 | 7 | $879.1M | 13F-HR |
| Q2 2021 | Jun 30, 2021 | Aug 16, 2021 | 5 | $706.5M | 13F-HR |
| Q1 2021 | Mar 31, 2021 | May 17, 2021 | 6 | $1.0B | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 16, 2021 | 7 | $1.1B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.